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Background: The role of systemic and myocardial adiponectin (ADN) in dilated cardiomyopathy is still debated. We
tested the regulation of both systemic and myocardial ADN and the relationship with AMP-activated protein kinase
(AMPK) activity in a swine model of non-ischemic dilated cardiomyopathy.
Methods and results: Cardiac tissue was collected from seven instrumented adult male minipigs by pacing the left
ventricular (LV) free wall (180 beats/min, 3 weeks), both from pacing (PS) and opposite sites (OS), and from five
controls. Circulating ADN levels were inversely related to global and regional cardiac function. Myocardial ADN in
PS was down-regulated compared to control (p < 0.05), yet ADN receptor 1 was significantly up-regulated (p <
0.05). No modifications of AMPK were observed in either region of the failing heart. Similarly, myocardial mRNA
levels of PPARγ, PPARα, TNFα, iNOS were unchanged compared to controls.
Conclusions: Paradoxically, circulating ADN did not show any cardioprotective effect, confirming its role as
negative prognostic biomarker of heart failure. Myocardial ADN was reduced in PS compared to control in an
AMPK-independent fashion, suggesting the occurrence of novel mechanisms by which reduced cardiac ADN levels
may regionally mediate the decline of cardiac function.
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Adiponectin (ADN) is an adipocyte-derived protein that
is abundantly present in plasma [1] and is also expressed
in cardiomyocytes [2] and endothelial cells [3]. Two
ADN receptors, AdipoR1 and AdipoR2, have been char-
acterized: AdipoR1 is abundantly expressed in skeletal
muscle, whereas AdipoR2 is predominantly expressed in
the liver [4]. T-cadherin, an additional ADN receptor, is
expressed in cardiomyocytes and is involved in ADN-
mediated cardioprotection [5]. The remodeling of the
failing heart has induced a number of investigators to
test the hypothesis that modulation of myocardial metabol-
ism might prove therapeutically advantageous [6].* Correspondence: danielag@ifc.cnr.it
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reproduction in any medium, provided the orPotential downstream effectors of ADN receptors in-
clude AMP-activated protein kinase (AMPK) and peroxi-
some proliferator-activated receptor-α (PPAR-α). AMPK
is considered an energy-sensing enzyme that on stimula-
tion enhances glucose use and fatty acid oxidation,
whereas PPAR-α is a key nuclear transcription factor,
regulating expression of genes involved in fatty acid up-
take and use [7]. It was recently shown that cardiac ADN
and its receptors are elicited by PPAR-γ activation, con-
firming the role of ADN in maintaining myocardial energy
homeostasis [2].
In addition, cardioprotective effects of ADN have been
well-demonstrated [8-11]. Many clinical studies have
shown that ADN is inversely correlated with an
increased cardiovascular risk, and hypo-adiponectinemia
has been established as an independent cardiovascular
risk factor in coronary artery disease [12-17]. Similarly,
in patients with dilated cardiomyopathy (DCM) withoutLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ciated with severe endothelial/microvascular dysfunction
[18]. Conversely, in patients with overt HF, ADN levels
are increased [19] in presence of an increased mortality
risk [20]. Further investigation of the autocrine/paracrine
role of the cardiac ADN system in the failing heart at
different stages could aid in understanding the “ADN
paradox” [21]. This issue is still debated and little infor-
mation is available.
The main aim of our study was to assess the regional
modulation of ADN system in a clinically relevant model
of non-ischemic HF, both at cardiac and systemic circu-
lating levels. For this purpose, the myocardial expression
of ADN, ADN receptors and modulators was deter-
mined in an experimental model of LV-pacing induced
HF [22] and compared with healthy myocardium. ADN
signaling was investigated to address myocardial remod-
eling, inflammation and metabolic process in different
regions of the non-ischemic failing left ventricle (LV)
regarding biochemical and functional patterns.
Methods
Experimental animal protocol
A total of twelve male adult minipigs (30–40 kg bw)
were studied. Non-ischemic HF was induced in seven
animals by epicardial pacing of the left ventricle (LV) at
180 beats/min for 3 weeks. Minipigs were sedated with a
cocktail of tiletamine hydrochloride and zolazepam
hydrochloride (8 mg/kg im) and premedicated with atro-
pine sulfate (0.1 mg/kg im). General anesthesia was sub-
sequently induced with propofol (2–4 mg/kg iv) and
maintained with 1–2% isoflurane in 60% air and 40%
oxygen. A thoracotomy was performed in the left fifth
intercostal space, then a catheter was inserted in the
descending thoracic aorta and a solid-state pressure
gauge (Konigsberg Instruments) inserted in the left ven-
tricle (LV) through the apex. A Doppler flow probe
(Craig Hartley) was placed around the left anterior des-
cending coronary artery, and a screw-type unipolar, epi-
cardial pacing lead (5071 IS-1 UNI; Medtronic, Inc) was
attached to the LV free wall, approximately 3 cm distal
to the atrioventricular margin. A programmable pace-
maker (PREVAILTM, Medtronic, Inc) was implanted in
a subcutaneous pocket. Baseline measurements were
taken after 7–10 days of post-surgical recovery. Pigs
were considered to be in severe HF when left ventricular
end-diastolic pressure was ≥ 20 mmHg. Hemodynamic
and magnetic resonance imaging (MRI, 1.5 Tesla) mea-
surements were performed at baseline and after 21 days
of pacing in sedated animals as previously described
[22,23]. The minipigs were finally sacrificed by injecting
saturated KCl solution intravenously after deep sedation
with 3.3 mg/kg of propofol. The heart was quickly
removed and cardiac tissue samples immediately placedin ice-cold RNAlater (Qiagen, Germany) and formalin
solution, neutral buffered, 10% (Sigma-Aldrich, St. Louis,
MO, USA) stored at −80°C. For our analysis, we selected
LV regions surrounding the site of pacing, i.e., the an-
terior and anterior-lateral regions, called pacing site
(PS), and remote from the pacing site, i.e., the inferior
and septal-inferior regions, called opposite site (OS).
Five healthy minipigs were also studied as controls.
Before and after the procedure, peripheral blood sam-
ples were withdrawn from animals in tubes containing
EDTA (1 mg/mL) and plasma samples were stored at
−20°C in aliquots. Animal instrumentation and experi-
mental protocols were approved by the Animal Care
Committee according to Italian legislation, following
the National Institute of Health publication Guide for
Care and Use of Laboratory Animals.
Cardiac MRI measurements
Cine-MRI images were acquired with a 1.5 Tesla MRI
scanner (Signa Excite HD, GE Medical Systems, Waukesha,
WI, USA) in sedated animals with continuous infusion of
midazolam (0.1 mg•kg-1•h iv) at spontaneous heart rate.
As previously described by us and by others [23,24] global
(end-diastolic volume, end-systolic volume, and ejection
fraction) LV parameters of contractile function were ana-
lyzed in pacing-induced HF with a commercially available
research software package (Mass Analysis, Leyden, The
Netherlands). To regionally assess the presence of tissue
fibrosis, gadolinium-delayed contrast-enhanced images
were acquired in two-dimensional segmented inversion
recovery-prepared gradient echo sequence 10 min after
administration of contrast agent Gd-DTPA (0.2 mmol/
kg iv) in short-axis views.
RNA and protein extraction
Total RNA and proteins were extracted from LV samples
by TRI-REAGENT (MRC, Inc, Cincinnati, OH, USA), as
previously described [25]. Total RNA was purified by
RNeasy Kit and DNase I (Qiagen, Germany). The extracted
RNA was solubilized in RNase-free water and quantified
spectophotometrically at 260 nm. The ratio of O.D. values
at 260 nm and 280 nm provided an estimate of RNA pur-
ity. For each sample, the RNA integrity was evaluated by
electrophoresis in a 1.5% agarose gel. The proteins
extracted from the organic phase were quantified by Lowry
protein assay, using bovine serum albumin as standard.
mRNA expression analysis (RT-PCR)
For each sample, 5 μg of total RNA were reverse tran-
scribed to cDNA by iScript cDNA Synthesis Kit
(Biorad, Hercules, CA, USA) in 100 μL of total reaction
volume, according to the manufacturer’s instructions.
The expression of ADN, AdipoR1, AdipoR2, T-cadherin,
brain natriuretic peptides (BNP), tumor necrosis
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were performed using specific primers and conditions
(Table 1). All PCR reactions were performed in a 20-μl
total volume, containing 0.5 U of Taq polimerase
(Qiagen, Germany), deoxyribonucleotide triphosphate
(dNTP) 0.4 mM, MgCl2 1.5 mM and forward and
reverse primers, 200 nM each. To avoid the errors
related to the common practice of using only one
control gene, the three most stable reference genes
selected from different abundance and functional
classes in porcine cardiac tissue [26], glyceraldehyde
3-phosphate dehydrogenase (GAPDH), hypoxanthine
phosphoribosyltransferase 1 (HPRT-1) and TATA
binding protein (TBP), were evaluated using specific
primers and specific PCR conditions (Table 1) and
their geometric mean was used as normalization factor
[27]. PCR products were separated on 1.5% agarose
gel and stained with GelStarNucleic Acid Gel Stain
(Cambrex East Rutherford, NJ, USA). Pictures of result-
ing gels were taken with digital camera and image ana-
lysis was performed by QuantityOne Software (Biorad).Table 1 Sequence of RT-PCR primer pairs for analyzed genes
Primer GenBank Sequence
ADN EF601160.1 Forward: ATCTGGA
202 bp Reverse: TTTGCCA
AdipoR1 AB527058.1 Forward: AACCCA
334 bp Reverse: CTGAGCA
AdipoR2 NM_001007192 Forward: GCCTGG
650 bp Reverse: GCCGATC
T-CAD NM_001109945.1 Forward: CCCGGG
217 bp Reverse: GGTAGAA
PPAR-α NM_001044526.1 Forward: TCGCGG
431 bp Reverse: GTCGTCC
PPAR-γ DQ437884.1 Forward: AGGAGC
391 bp Reverse: AGCAAAC
BNP M25547 Forward: GTGCTCC
451 bp Reverse: TCCCAGG
iNOS NM_001143690.1 Forward: GAGGGC
264 bp Reverse: GGCCAGC
TNF-α EU682384.1 Forward: ATCGGC
351 bp Reverse: GATGGCA
GAPDH AF017079 Forward: ACCACA
451 bp Reverse: TCCACCA
HPRT1 DQ178126 Forward: CCGAGG
181 bp Reverse: CTATTTCT
TBP DQ178129 Forward: GATGGA
124 bp Reverse: AGCAGCA
Adiponectin (ADN), AdipoR1, AdipoR2, T-cadherin (T-CAD), peroxisome proliferator-
nitric oxide synthase (iNOS), tumor necrosis factor (TNF)-α, glyceraldehyde 3-phosph
(HPRT-1) and TATA binding protein (TBP).Western blotting
Total proteins obtained from cardiac tissue or plasma
samples were subjected to western blot analysis after so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), under reducing and denaturating condi-
tions. After boiling at 95°C for 5 min, samples (70 μg of
total protein or 2 μL of plasma per lane) were subjected
to SDS-PAGE on 10% polyacrylamide gel and then
transferred to polyvinylidene fluoride (PVDF) membrane
for ADN and nitrocellulose membrane for phospho-
AMPKα and AMPKα. Nonspecific binding was blocked
by incubation with 5% nonfat dry milk for 3 h. The
membranes were incubated overnight at 4°C with pri-
mary antibody against ADN (1:2000, Millipore, Billerica,
MA, USA); AMPKα (1:1000, Cell Signaling Technologies,
Boston, MA, USA) and phospho-AMPKα(1:1000, Cell
Signaling Thecnologies). After washing, the membranes
were incubated with anti-rabbit biotinilated (1:20000,
Enzo Life Sciences International, Plymouth Meeting, PA,
USA) or anti-mouse biotinilated (1:10000, Enzo Life
Sciences International) for 1 h at room temperature andTa, °C Cycles, n
GTGACTGGGGTTG 61 36
GTGGTGACATCAT
CCCAAAGCTGAAGA 58 29
TGGTCAAGATTCC
GGATCTTTTATATGTTTC 53 34
ATGAAACGAA
CAGAGCTTCGAAAT 64 25
AACCGGGCCCTCG
GAAAGGCCAGCAAT 70 27
AGCTCCAGCGCATT
ATAGCAAAGAGGTGGCC 70 32
CTGGGCGGTCTCCA
TGCTCCTGTTCTT 61 35
CTTCTGTGAGG
AGCCAAGGCCCAAG 65 35
TTTCGGAGCAGCA
CCCCAGAAGGAAGAC 64 33
GAGAGGAGGTTGAC
GTCCATGCCATCAC 60 30
CCCTGTTGCTGTA
ATTTGGAAAAGGT 60 30
GTTCAGTGCTTTGATGT
CGTTCGGTTTAGG 60 30
CAGTACGAGCAA
activated receptor (PPAR)-α, PPAR-γ, brain natriuretic peptides (BNP), inducible
ate dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase 1
Table 2 Global and regional LV function
Baseline 3 weeks of LV pacing
Heart Rate, bpm 94±6 122±8*
MAP, mmHg 109±8 77±8.4*
LVEDP, mmHg 5.5±3.04 20.5±6*
LV dP/dtmax , mmHg/s 2400±220 1388±188*
LV EDV, ml 65±5 85±7.2*
LV ESV, ml 15±3.4 54.4±7.6*
LV EF, % 76.9±2 36±1.8*
LV ESWT (PS), % 63±3.2 5±1.2*
LV ESWT (OS), % 62±2.5 40±1.8*
Values are means±SE. MAP, mean arterial pressure; LVEDP, left ventricular end
diastolic pressure; EDV, end diastolic volume; ESV, end systolic volume; EF,
ejection fraction; ESWT end systolic wall thickening; PS, pacing site; OS,
opposte site. n= 7.
* vs Baseline, p<0.05.
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conjugated streptavidin (1:2000, Biorad) for 30 min at
room temperature. Sample loading was normalized by
immunoblotting with anti-tubulin polyclonal antibody
(1:500, Serotec, Oxford, UK). Proteins were visualized
by colorimetric reaction using opti-4CN, (Biorad) and
analyzed using QuantityOne Software (Biorad).
Histochemistry and immunohistochemistry
Formalin-fixed tissue specimens were embedded in par-
affin. Five-micron-thick sections were cut and serially
mounted on glasses. Sections were stained with hema-
toxilin and eosin stain and van Gieson’s counterstain, to
detect myocardial collagen deposits. Immunohistochemical
analysis was performed to detect ADN. Briefly, sections
were treated as follows: microwave antigen retrieval (700
W for 7 min, twice in 10 mM sodium citrate, pH 6.0);
hydrogen peroxide (3% in PBS 1X) to block endogenous
peroxidase and normal goat serum (10% in PBS 1X) to
block non-specific bindings. ADN was detected by incuba-
tion overnight at 4 °C with the primary antibody (1:500,
Millipore). Antibodies were diluted in PBS containing
0.1% goat serum and 0.1% TRITON. Sections were
sequentially incubated with biotinylated anti-rabbit
anti-serum (1:500, Enzo Life Sciences International),
horseradish peroxidase–streptavidin complex (1:1000,
Biorad), 3,3¢-diaminobenzidine tetrahydrocloride (DAB).
Specimens were counterstained with hematoxylin (1:30),
mounted with DPXÒ mountant for histology (Fluka,
Buchs, Switzerland) and examined by light microscope.
Negative controls were obtained by using secondary
goat serum (1:100).
Circulating and cardiac TNF-α measurement
Arterial blood samples were collected during the imaging
acquisition. Plasma levels as well as myocardial concen-
trations of porcine TNF-α were measured in duplicate by
a specific ELISA kit (Thermo Scientific/Pierce, Rockford,
IL, USA), with an assay range of 31.3–2000 pg/mL and a
sensitivity < 5.0 pg/mL.
Statistical analysis
Data are reported as media ± SEM. Statistical comparisons
were performed between PS, OS and controls by statistical
software (SPSS 16.0 for Mac, Chicago, IL, USA). Differ-
ences between groups were compared by ANOVA fol-
lowed by the Fisher post hoc test. A two-tailed P-value
< 0.05 was considered statistically significant.
Results
Global and regional LV function
Hemodynamic and MRI parameters of HF animals are
reported in Table 2. All animals displayed the typical
alterations of HF, including significant reduction of LVejection fraction (LVEF) compared to healthy animals
and increase of LV end-diastolic pressure (LVEDP),
which reached 20 ± 6 mmHg after 21 ± 2 days of pacing.
This is considered a stage of severe, although not ter-
minal, HF [22].Circulating and cardiac ADN
Circulating ADN levels measured by Western blotting
increased significantly (p = 0.031) in pigs after 21 days
of pacing (Figure 1A).
The presence of ADN in cardiac muscle was checked
by RT-PCR, western blotting and immunohistochemistry.
ADN mRNA expression was downregulated in HF car-
diac samples (Figure 1B), and it was significantly lower in
PS compared to controls (p = 0.041). As showed in
Figure 1C, myocardial ADN protein expression was very
low. Similarly, ADN was weakly detected by immunohis-
tochemistry in extracellular matrix surrounding vessel
walls of PS, whereas no signal was detected in histo-
logical section of LV samples from OS and healthy ani-
mals (Figure 1D).ADN receptors
mRNA expression of ADN receptors in cardiac muscle
was determined by RT-PCR (Figure 2). As expected, in
porcine heart AdipoR1 was expressed more than Adi-
poR2, as shown by the lower number of PCR cycles used
to obtain the right number of cDNA copies in RT-PCR
analysis (Table 1). AdipoR1 was significantly upregulated
in PS when compared to OS (p = 0.044) and controls
(p = 0.024) and showed a negative correlation with
ADN mRNA expression (r = −0.717, p = 0.001). Myo-
cardial AdipoR2 and T-cadherin mRNA expression in
failing heart was unchanged compared to control. A
positive correlation between the AdipoRs was observed
(r = 0.582, p = 0.009).
Figure 1 ADN presence in both plasma and cardiac tissue. A) Circulating levels of ADN measured by Western Blotting before the beginning
of the experimental protocol and after 21 days of pacing induction (n = 7); B) ADN expression at mRNA level from PS, OS and controls; C)
relative blots of circulating levels of ADN (a); mRNA expression of ADN (b) as well as housekeeping genes, GAPDH (c), HPRT-1 (d), TBP (e)
measured by RT-PCR and immunoblots of ADN by Western blot (f); D) representative immunostaining of ADN from heart sections showing the
extra-cellular localization of ADN in peri-vascular tissue of PS.
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To understand the mechanism underlying ADN system
modification, mRNA expression of PPARγ, an upstream
ADN regulator [8], was determined in each region, but
no changes compared to control were observed in PS
and OS (Figure 3A). To investigate the relationship
between the inflammatory process and ADN level incardiac tissue, TNF-α expression was measured in
both cardiac tissue and peripheral circulation. Myocardial
TNF-α level in HF animals did not show any significant
change compared to controls at both mRNA (Figure 3B)
and protein expression (7.82 ± 2.04 pg/mg of total
protein in PS, 8.85 ± 2.36 in OS, 8.53 ± 2.40 in con-
trols, p = ns). TNF-α was not detected in peripheral
Figure 2 ADN receptors in cardiac tissue from both PS and OS as well as in control hearts. A) relative blots of AdipoR1 (a), AdipoR2 (b)
and T-cadherin (c) RT-PCR products; B) mRNA expression of Adipo R1; C) AdipoR2, and D) T-cadherin.
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pacing. No inflammatory cells were detected in either re-
gion of the failing heart as nor in controls (Figure 3E),
confirming the lack of inflammation. Finally, we found
that ADN is inversely correlated with BNP (P < 0.05)
(Figure 3D).ADN signaling
Figure 4A shows the results of RT-PCR and WB analysis
performed in healthy and failing hearts. To explore the
relationship between ADN and metabolism as well as
apoptotic pathways, the regional activation of AMPKα
and PPARα expression were investigated. As shown in
Figure 4B, the myocardial expression and phosphoryl-
ation of AMPKα showed no changes in failing hearts
compared to controls. In addition, the expression of
PPARα (Figure 4C) and iNOS in HF PS and OS was
equal to that in controls.Cardiac remodeling
Histological measures in HF PS and OS revealed no dif-
ference in collagen deposits compared to controls, yet a
weak positive stain was detected in the perivascular area
of the pacing site (Figure 4E), confirming the absence of
gross myocardial fibrosis in presence of severe regional
contractile failure [22].Discussion
We investigated the myocardial ADN pathway in a clin-
ically relevant animal model of non-ischemic dilated car-
diomyopathy. The main findings of our study are: first,
increased circulating ADN levels in HF minipigs did not
affect myocardial AMPK expression and activity, nor
PPARα expression; second, sustained high-rate LV
pacing caused a significant reduction of ADN level and
increased AdipoR1 level in PS, but not in OS; third, re-
gional ADN down-regulation was related to severe con-
tractile impairment, yet the key regulators of altered
cardiac metabolism, inflammation and remodeling were
unchanged compared to control hearts.
High circulating ADN levels have been reported re-
peatedly in HF [19-21,28] and several mechanisms have
been utilized to explain this increase. Recent studies
have reported that natriuretic peptides enhance ADN
production via the cGMP pathway, by human adipocytes
both in vitro and in vivo in patients with HF [29,30]. We
have previously described that BNP and CNP expression
increased in adult minipigs after 21 days of LV pacing
[25]. It is well-known that natriuretic peptides are
secreted almost exclusively by cardiac tissue and their
levels are increased in patients with HF [31]. It has been
hypothesized that the ADN increase could be a compen-
satory effect in order to restore metabolic homeostasis,
due to its anti-inflammatory and insulin-sensitizing
effects [32,33]. Abnormalities in glucose regulation, such
Figure 3 ADN regulation. A) mRNA expression of PPARγ and B) TNFα in PS, OS and controls C)as well as relative blots of RT-PCR products D);
relationships between ADN and BNP mRNA expression; E) representative immunostaining of hematoxilin and eosin stain from heart sections.
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have been shown to correlate with HF severity [34]. In
our animal model, we previously found that plasma in-
sulin concentration was significantly higher in HF com-
pared to control in presence of homogenous LV increase
of glucose uptake [22]. In our study, no change was
observed in AMPK activity and PPARα expression in
presence of a marked reduction of global and regional
LV function. The lack of cardiac activation of the ADN
downstream molecules could suggest that their asso-
ciated cardiac effects are not related to high ADN
plasma levels. This may agree with previous studies
reporting an association between high levels of ADN in
HF and severity as well as increased mortality, indicating
for ADN a role as prognostic biomarker of HF [20,21].
Based on these findings, a “functional ADN resistance”in HF at the receptor level has been hypothesized. This
resistance could determine an attenuated ADN response
during the progression of HF [21], as recently observed
at the level of skeletal muscle in chronic HF [35]. In this
paper, a strong positive correlation between AdipoR1
and PPARα/AMPK gene expression was found. In our
study, we found an increased expression of AdipoR1 in
the HF pacing site in presence of myocardial ADN
mRNA down-regulation, yet PPARα/AMPK gene ex-
pression and AMPK activity were not significantly differ-
ent from healthy heart. As to T-cadherin, a physical
association of ADN with T-cadherin is a prerequisite for
ADN’s physiological activity in the heart [5]; thus, the re-
duction of T-cadherin mRNA expression in failing heart,
although not significant, could support the reduced ac-
tivity of ADN/AdipoR system in this condition.
Figure 4 Cardiac molecular pathways involved in ADN signaling. A) relative immunoblots of pAMPK and AMPK as well as mRNA expression
of PPARα and iNOS; B) the ratio of phospho-AMPK and AMPK in PS, OS and controls; C) mRNA expression of PPARα; D) mRNA expression of
iNOS; E) van Gieson’s staining of heart section from PS, OS and controls.
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expression (Figure 1) as well as the presence of a regional
variation in myocardial tissue after pacing are in tune
with the existence of a local cardiac ADN regulation, in-
dependent of the circulating ADN, as previously
described in human [36,37] and murine hearts [38]. The
cardiac protein expression of ADN in our samples was
difficult to detect. We detected small amounts of ADN in
the extracellular matrix surrounding the injured areas of
the PS, but not in OS and controls. Consistent with these
findings, previous studies have reported the presence of
ADN in damaged regions of the heart, also due to its
leakage from the vascular section [39-41]. Moreover,
down-regulation of ADN mRNA expression, compared
to controls, and the myocardial over-expression of Adi-
poR1 in PS suggested the existence of a possible feedback
loop, as previously observed in skeletal muscle [35].
The mechanisms underlying this down-regulation are
yet unknown. It is well-recognized that inflammatorycytokine production, particularly TNF-α, plays a critical
pathogenic role in cardiovascular complications, and a
reciprocal action between TNF-α and ADN exists
[42,43]. However, in our model we found that cardiac
ADN was down-regulated in absence of inflammatory
response. In fact, TNF-α at the mRNA and protein level,
was unchanged in each region of failing left ventricle
and no inflammatory cells were detected. Accordingly,
myocardial expression of PPAR-γ, a known upstream
regulator of ADN [2], was also unchanged in each region
of the failing heart. On the other hand, Sturk et al. pro-
vided evidence, directly in cardiomyocytes, of a cardiac
regulatory feedback loop in ADN expression, without
identifying any specific cardiomyocyte-derived secreted
factors that exert this negative feedback [36]. Otherwise,
a negative relationship between ADN and BNP mRNA
expression was observed in this study (Figure 3C), sug-
gesting that impaired contractile function in the failing
heart could affect the ADN/AdipoR1 system. In a recent
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tion, inverse correlations between myocardial ADN and
BNP as well as heparin-binding epidermal growth factor
(HB-EGF) were shown, indicating an important role for
ADN in mediating the myocardial hypertrophic signaling
pathway [38]. However, in our experimental animal
model, cardiac tissue did not develop hypertrophic re-
modeling, as shown by the collagen immunohistochem-
istry (Figure 3E). The lack of collagen deposits in PS in
absence of coronary stenosis and inflammation suggests
the occurrence of non-ischemic ventricular remodeling
due to mechanical stress, which could impair the cardiac
ADN/AdipoR1 system. Sen et al. [44] demonstrated
in vitro that continuous mechanical strain inhibits ADN
expression at the transcriptional level.
As a matter of fact, it has been suggested that ADN
may directly protect cardiomyocytes [37] largely via an
AMPK-mediated signal pathway [9]. However, the lack of
variation of AMPK expression and activity in our animal
model supports the hypothesis that other pathways drive
the cardioprotection afforded by ADN. In fact, treatment
with ADN is still effective in improving the cardiac func-
tion in AMPK knockout mice [45]. The cardioprotective
action of ADN may be performed by suppression of
TNF-α signaling via the COX-2-prostaglandin E2-linked
cascade [46]. In our conditions, TNF-α did not show any
changes between HF and controls either at mRNA or
protein level (Figure 4). In addition, it has been reported
that ADN might prevent excess NO generation by inhi-
biting iNOS expression [45]. In our model, no significant
variation of iNOS expression was found in HF compared
to controls and no correlation with myocardial ADN was
observed.
Limitations
Other downstream ADN signalling pathways such as
ceramides [47,48] and other factors besides ADN that
could affect the transduction signalling [49,50] exist;
however, the samples collected in our study are incon-
sistent for their evaluation. The main limitation of this
study is the impossibility of evaluating these further
mechanisms involved in both ADN and AMPK
signalling.
Conclusions
Our findings were observed in a reliable translational
animal model of non-ischemic HF. The pacing-induced
HF model is considered the gold standard in HF experi-
mental research due to its relative similarities with many
features of clinical dilated cardiomyopathy [51]. In con-
clusion, we observed that in spite of its high peripheral
concentrations, plasma ADN did not show cardioprotec-
tive effects, confirming its role as a negative prognostic
biomarker of HF. In particular, the effect of adiponectinin non-ischemic HF is AMPK-independent. These obser-
vations suggest the occurrence of novel mechanisms by
which reduced cardiac ADN levels may regionally medi-
ate the decline of cardiac function.
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proliferator-activated receptor α; PPAR-γ: Peroxisome proliferator-activated
receptor γ; PS: Pacing site; RT-PCR: Reverse trascriptase polymerase chain
reaction; TBP: TATA binding protein; T-CAD: T-cadherin; TNF-α: Tumor
necrosis factor α.
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